Compare Novo Nordisk A/S (NVO) vs Rocket Companies Inc. Class A Common Stock (RKT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Rocket Companies Inc. Class A Common Stock — how do they compare? Novo Nordisk A/S trades at $38.59 (market cap $169.08B), while Rocket Companies Inc. Class A Common Stock trades at $10.69 (market cap $30.67B). The key difference: Novo Nordisk A/S is far larger — about 5.5× Rocket Companies Inc. Class A Common Stock's market cap, and Novo Nordisk A/S pays a 4.72% dividend while Rocket Companies Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Rocket Companies Inc. Class A Common Stock for 0 Days on average.
| NVO | RKT | |
|---|---|---|
Market Cap | $169.08B | $30.67B |
Volume | 9,259,152 | 41,104,143 |
Sector | Health | Financials |
52-Week High | $63.98 | $23.44 |
52-Week Low | $35.29 | $10.53 |
Typical Hold Time | 116 Days | 0 Days |
Enterprise Value | $183.28B | $60.66B |
Dividend Yield | 4.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.12, down 1.19% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 EPS of $0.96, beating expectations by 17%, continuing a trend of earnings outperformance. Valuation metrics remain attractive with P/E of 9.67 and ROE of 59.82%, while recent news highlights pipeline expansion through $4 billion in licensing deals and progress on oral Wegovy formulations.
The stock presents a compelling value opportunity with strong profitability and growth prospects in obesity/diabetes markets, though technical weakness and competitive pressure from Eli Lilly create near-term headwinds. Analyst consensus remains bullish with $42.33 price target representing 11% upside potential from current levels.
Rocket Companies (RKT) trades at $10.83, down 0.37% on the day, with a neutral technical signal and mixed earnings history. The stock is near its 52-week low amid a challenging mortgage market. Recent financials show a net loss of $68 million in 2025 but project a return to profitability in 2026. Analyst consensus is a 'Buy' with a $16.88 price target, though sentiment is tempered by high interest rates and housing market pressures.
Outlook: RKT offers potential upside from current depressed levels if mortgage demand recovers, but faces significant headwinds from persistent high rates and weak housing activity. Risks include competitive pressures and regulatory scrutiny, while opportunities lie in market share gains and cost management improvements. Investors should weigh the cyclical recovery potential against near-term macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Rocket Companies Inc. Class A Common Stock
Rocket Companies, Inc. operates a homeownership platform spanning mortgage origination and servicing, real estate, title and closing, and personal finance, with flagship brands including Rocket Mortgage, Rocket Close, Rocket Money, Rocket Loans, and Redfin.
Read more on RKT →
